Advertisement
Advertisement

HRTX

HRTX logo

Heron Therapeutics, Inc.

0.42
USD
Sponsored
-0.01
-3.30%
Jun 25, 12:34 UTC -4
Open

HRTX Earnings Reports

Positive Surprise Ratio

HRTX beat 21 of 41 last estimates.

51%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$43.04M
/
$0.01
Implied change from Q1 26 (Revenue/ EPS)
+24.01%
/
-125.00%
Implied change from Q2 25 (Revenue/ EPS)
+15.71%
/
-150.00%

Heron Therapeutics, Inc. earnings per share and revenue

On May 11, 2026, HRTX reported earnings of -0.04 USD per share (EPS) for Q1 26, missing the estimate of -0.01 USD, resulting in a -161.44% surprise. Revenue reached 34.71 million, compared to an expected 39.12 million, with a -11.26% difference. The market reacted with a -21.05% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 0.01 USD, with revenue projected to reach 43.04 million USD, implying an decrease of -125.00% EPS, and increase of 24.01% in Revenue from the last quarter.
FAQ
For Q1 2026, Heron Therapeutics, Inc. reported EPS of -$0.04, missing estimates by -161.44%, and revenue of $34.71M, -11.26% below expectations.
The stock price moved down -21.05%, changed from $1.21 before the earnings release to $0.96 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on -- analysts, Heron Therapeutics, Inc. is expected to report EPS of $0.01 and revenue of $43.04M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement